New candidate products for ischemic stroke developed by Korean pharmaceutical companies are proving to be effective. As global pharmaceutical companies have faced difficulties in development, attention is drawn to the possibility of commercializing new stroke drugs made in Korea.

According to industry experts on the 17th, Phase 3 clinical demonstrated the efficacy of Nelonemdaz, a new ischemic candidate product developed by the bioventure company GNT Pharma.

Nelonemdaz is a derivative of aspirin and sulfasalazine, selectively inhibiting the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor, a receptor of glutamate. This drug can prevent neuronal injury after surgical thromb